Local Anesthetic Properties of Prenylamine Mustafa G

Total Page:16

File Type:pdf, Size:1020Kb

Local Anesthetic Properties of Prenylamine Mustafa G Anesthesiology 2001; 95:1198–1204 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Local Anesthetic Properties of Prenylamine Mustafa G. Mujtaba, Ph.D.,* Peter Gerner, M.D.,† Ging Kuo Wang, Ph.D.‡ Background: Local anesthetics that produce analgesia of long of the L-type calcium channels.3 Both ␣-subunits form a duration with minimal impairment of autonomic functions are fourfold pseudosymmetry with four repeated domains, highly desirable for pain management in the clinic. Pre- each with six transmembrane segments.3 There are nylamine is a known calcium channel blocker, but its local anesthetic blocking effects on voltage-gated sodium channels drugs that can block both calcium channels and 4,5 have not been studied thus far. NaChs. It has been reported that there is a correlation Methods: The authors characterized the tonic and use-depen- between the potencies of calcium channel blockers in ؉ dent prenylamine block of native Na channels in cultured rat preventing neurotoxicity induced by veratridine in brain neuronal GH cells during whole cell voltage clamp conditions Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/95/5/1198/334086/0000542-200111000-00025.pdf by guest on 02 October 2021 3 neuronal cultures and their binding affinity for and the local anesthetic effect of prenylamine by neurologic 3 6 evaluation of sensory and motor functions of sciatic nerve dur- [H ]batrachotoxinin-B binding sites. This raises a possi- ing neural block in rats. bility that some calcium channel blockers may block .Results: Prenylamine elicits both use-dependent block of Na؉ Naϩ channels with a high affinity channels during repetitive pulses (3 ␮M prenylamine produced Few LAs for pain management produce analgesia of 50% block at 5 Hz) and tonic block for both resting and inacti- ؉ long duration. The development and availability of such vated Na channels. The 50% inhibitory concentration for pre- -nylamine was 27.6 ؎ 1.3 ␮M for resting channels and 0.75 ؎ LAs that can cause reversible blockade of neural func 0.02 ␮M for inactivated channels. Furthermore, in vivo data tions is desirable and advantageous for certain pain man- show that 10 mM prenylamine produced a complete sciatic agement in the clinic. Prenylamine, a coronary vasodila- nerve block of motor function, proprioceptive responses, and tor, is a calcium channel blocker formerly used in the nociceptive responses that lasted approximately 27, 34, and treatment of angina pectoris but now superseded by 24 h, respectively. Rats injected with 15.4 mM bupivacaine, a 7–10 known local anesthetic currently used for pain management, safer antianginal drugs. The general pharmacologic had a significantly shorter duration of blockade (< 2 h) com- activities, including surface anesthesia, of prenylamine pared with rats injected with prenylamine. and some of its cycloalipahtic derivatives have been Conclusions: The data presented here demonstrate that pre- previously studied.11 The LA properties of prenylamine nylamine possesses local anesthetic properties in vitro and on voltage-gated NaChs have not been characterized elicits prolonged local anesthesia in vivo. thus far. We selected prenylamine because it contains large hydrophobic moieties (fig. 1). Previous results in- TRADITIONAL local anesthetics (LAs) block voltage- dicate that LAs with two large hydrophobic moieties are gated sodium channels (NaChs) and inhibit the propaga- more potent in vivo.12,13 This study examines the LA tion of action potentials in excitable membranes. Volt- properties of prenylamine in vitro by electrophysiologic age-gated NaChs are the main target of LAs. LAs are studies of the NaCh on neuronal GH cells and assesses known to block nerve, skeletal, muscle, and cardiac 3 its usefulness as a long-acting LA in vivo by neurobehav- muscle NaChs, which are primarily responsible for ex- ioral examination of sciatic nerve block in the rat in citability of their respective tissue. LA potency, as Naϩ comparison with the known LA anesthetic bupivacaine. channel blockers, is governed by channel state, with open and inactivated states being favored over resting states. Voltage-dependent conformational changes of the Materials and Methods LA binding site can explain the changes of LA affinity between resting, open, and inactivated states.1 Prenylamine and Bupivacaine There are structural similarities between voltage-gated Prenylamine was purchased from Sigma Chemical Co. sodium and calcium channel proteins, even though (St. Louis, MO). Bupivacaine was a gift from AstraZeneca, these two channels differ strongly in their ion selectivi- (Westborogh, MA). For the electrophysiologic experi- ty.2 The homologous domains of the ␣-subunit of NaChs ments, prenylamine and bupivacaine were dissolved in can be aligned with 32–37% sequence identity with that dimethyl sulfoxide at 100 mM and were diluted shortly before the experiments. For sciatic nerve blockade, pre- nylamine was dissolved in 5% dextrose solution and * Research Fellow, † Instructor in Anesthesia, ‡ Associate Professor of bupivacaine in 0.9% sodium chloride solution. Pre- Anesthesia. nylamine is insoluble in saline solutions; thus, 5% dex- Received from the Department of Anesthesia Research Laboratories, Brigham trose was used as the vehicle of transfer for injection. and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. Submitted for publication February 21, 2001. Accepted for publication May 30, Neither 0.9% sodium chloride nor 5% dextrose solution 2001. Supported by grant No. GM48090 from the National Institutes of Health, had any analgesic effect. Bethesda, Maryland (to Dr. Wang). Address reprint requests to Dr. Mujtaba: Department of Anesthesia Research Laboratories, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massa- Neurologic Evaluation of Sciatic Nerve Block in the Rat chusetts 02115. Address electronic mail to: [email protected]. In- dividual article reprints may be purchased through the Journal Web site, The following protocol, which we and other investi- www.anesthesiology.org. gators have used previously for the evaluation of sciatic Anesthesiology, V 95, No 5, Nov 2001 1198 PRENYLAMINE AS A POTENT LOCAL ANESTHETIC 1199 reflex or vocalization to pinch of a skin fold over the lateral metatarsus (coetaneous pain) and of the distal phalanx of the fifth toe (deep pain). Nocifensive reaction is graded 4 (normal: vocalization and withdrawal of hind limb, or 0% MPE), 3 (more slowly than control, or 25% MPE), 2 (not complete response, or 50% MPE), 1 (weak attempts to withdraw, or 75% MPE), and 0 (absent re- sponse, or 100% MPE). Whole Cell Voltage Clamp Experiments Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/95/5/1198/334086/0000542-200111000-00025.pdf by guest on 02 October 2021 Fig. 1. Chemical structures of prenylamine and bupivacaine. Rat clonal pituitary GH3 cells were purchased from the American Type Culture Collection (Rockville, MD). Cell nerve block in the rat,13,14 was approved by the Harvard cultures were split twice a week and maintained in Medical Area Standing Committee on Animals (Boston, Dulbecco modified Eagle medium supplemented with MA). Male Sprague Dawley rats were purchased from 1% penicillin–streptomycin and heat-inactivated 10% fe- Charles Rivers Laboratories (Cambridge, MA) and used tal bovine serum (Hyclone Labs, Logan, UT) in a 5% for in vivo experiments. Neurobehavioral examination carbon dioxide incubation chamber at 37°C. For record- consisted of evaluation of motor function, propriocep- ϩ ing of Na current, GH3 cells were replated in a 35-mm tion, and nocifensive reaction immediately before injec- culture dish, which was then used as a recording cham- tion of 0.2 ml of the drug solution and at various timed ber. The whole cell configuration of the patch clamp intervals after injection. Changes of function were esti- technique was used to record macroscopic Naϩ currents mated as percentage of maximal possible effect (MPE). at room temperatures ranging from 21 to 23°C. Pipette Motor function was evaluated by measuring the “exten- electrodes were fabricated with a tip resistance ranging sor postural thrust” of the hind limbs by holding the rat from 0.8 to 1.2 M⍀. Command voltages were controlled upright with the hind limb extended so that the distal by pCLAMP software (Axons Instruments, Inc., Foster metatarsus and toes support the animal’s weight and City, CA) and delivered by a List-EPC7 patch clamp measuring the extensor thrust as the gram force applied amplifier (List-Electronics, Darmstadt/Eberstadt, Germa- to a digital platform balance, the force that resists con- ny). After the establishment of whole cell configuration, tact of the platform by the heel. The preinjection control value is considered 0% of the MPE. The reduction in this cells were dialyzed for 20–30 min to equilibrate with the force, representing reduced extensor muscle contrac- pipette solution before data were acquired. Data were tion caused by motor blockade, was calculated as a filtered at 5 kHz, sampled at 50 kHz, collected, and percentage of the control force. A force less than 20 g stored with pCLAMP software. Voltage error was gener- ϩ (also referred to as weight of the “flaccid limb”) is con- ally less than 3 mV at 30 mV after series resistance sidered 100% MPE. Proprioception evaluation was based compensation. Leak and capacitance currents were sub- on the resting posture and postural reaction (“tactile tracted by P/-4 protocol, which was not applied in the ϩ placing” and “hopping”). The functional deficit was use-dependent block of Na currents. Pipette electrodes graded as 3 (normal) or 0% MPE, 2 (slightly impaired), 1 were filled with an internal solution containing 100 mM (severely impaired), and 0 (complete) or 100% MPE. NaF, 30 mM NaCl, 10 mM EGTA, and 10 mM HEPES Keeping the rat in the normal resting posture with titrated with CsOH to pH 7.2. The external solution the toes flexed and the dorsi of the feet placed on the consisted of 85 mM choline Cl, 65 mM NaCl, 2 mM CaCl2, supporting surface, we evaluated tactile placing as the and 10 mM HEPES titrated with tetramethylammonium- ability of the animal to reposition its toes.
Recommended publications
  • Gabab Regulation of Methamphetamine-Induced Associative Learning
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 2010 Gabab Regulation of Methamphetamine-Induced Associative Learning Robin Michelle Voigt Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Pharmacology Commons Recommended Citation Voigt, Robin Michelle, "Gabab Regulation of Methamphetamine-Induced Associative Learning" (2010). Dissertations. 38. https://ecommons.luc.edu/luc_diss/38 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 2010 Robin Michelle Voigt LOYOLA UNIVERSITY CHICAGO GABAB REGULATION OF METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY PROGRAM IN MOLECULAR PHARMACOLOGY & THERAPEUTICS BY ROBIN MICHELLE VOIGT CHICAGO, IL DECEMBER 2010 Copyright by Robin Michelle Voigt, 2010 All rights reserved ACKNOWLEDGEMENTS Without the support of so many generous and wonderful individuals I would not have been able to be where I am today. First, I would like to thank my Mother for her belief that I could accomplish anything that I set my mind to. I would also like to thank my dissertation advisor, Dr. Celeste Napier, for encouraging and challenging me to be better than I thought possible. I extend gratitude to my committee members, Drs. Julie Kauer, Adriano Marchese, Micky Marinelli, and Karie Scrogin for their guidance and insightful input.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • Educational Commentary – Testing for Amphetamines and Related Compounds
    EDUCATIONAL COMMENTARY – TESTING FOR AMPHETAMINES AND RELATED COMPOUNDS Learning Outcomes Upon completion of this exercise, participants will be able to: • list amphetamine-like compounds that may be detected by immunoassay screening tests for amphetamines. • describe the 3 types of amphetamine immunoassays based on their antibody specificity. • discuss common causes of false-positive results when testing for amphetamines. Correct interpretation of testing results for amphetamines and related compounds is dependent on many factors including an understanding of the nomenclature, structure, and metabolism of these compounds. The class of phenethylamine compounds having varying degrees of sympathomimetic activity include amphetamine, methamphetamine, and many other compounds known by several names including amphetamines (as a group), designer drugs often grouped together as ecstasy [3,4- methylenedioxymethamphetamine (MDMA); 3,4-methylenedioxyamphetamine (MDA), and 3,4- methylenedioxy-N-ethylamphetamine (MDEA)], and sympathomimetic amines including ephedrine, pseudoephedrine, and phenylpropanolamine found in over-the-counter (OTC) medications. Amphetamine, a primary amine, and methamphetamine, a secondary amine, have a stereogenic center and have enantiomers or optical isomers designated d (or +) for dextrorotatory and l (or -) for levorotatory. In general, the d isomers are the more physiologically active compounds, but pharmaceutical preparations may consist of either isomer or a mixture of both isomers. When the mixture contains equal concentrations of the 2 enantiomers, it is known as a racemic mixture. The existence of enantiomers for amphetamines creates analytical and interpretative problems. Immunoassay Screening The primary screening methods for detecting amphetamines are immunoassays. The structural similarity to amphetamine or methamphetamine of the compounds previously mentioned makes it difficult to produce antibodies specific for amphetamine, methamphetamine, or both.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Fendiline (hydrochloride) Item No. 17295 CAS Registry No.: 13636-18-5 Formal Name: γ-phenyl-N-(1-phenylethyl)- benzenepropanamine, monohydrochloride MF: C23H25N • HCl FW: 351.9 N Purity: ≥95% H Stability: ≥2 years at -20°C Supplied as: A crystalline solid • HCl Laboratory Procedures For long term storage, we suggest that fendiline (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. Fendiline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the fendiline (hydrochloride) in the solvent of choice. Fendiline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of fendiline (hydrochloride) in these solvents is approximately 15, 30, and 20 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of fendiline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of fendiline (hydrochloride) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day. α Fendiline is an 2-adrenergic receptor antagonist (Kd = 2.6 µM) and an L-type calcium channel blocker (IC50 = 17 µM) well-known for its coronary vasodilator effects.1-4 Fendiline has recently been reported to inhibit K-Ras plasma membrane localization (IC50 = 9.64 µM), which prevents K-Ras signal transduction and blocks the proliferation of K-Ras-transformed tumor cells.5 References 1.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • MRO Manual Before 2004
    Note: This manual is essentially the same as the 1997 HHS Medical Review Officer (MRO) Manual except for changes related to the new Federal Custody and Control Form (CCF). The appendix has also been deleted since the new Federal Custody and Control Form is available as a separate file on the website. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs for use with the new Federal Drug Testing Custody and Control Form (OMB Number 0930-0158, Exp Date: June 30, 2003) This manual applies to federal agency drug testing programs that come under Executive Order 12564 and the Department of Health and Human Services (HHS) Mandatory Guidelines. Table of Contents Chapter 1. The Medical Review Officer (MRO) ............................................................... 1 Chapter 2. Federal Drug Testing Custody and Control Form .......................................... 3 Chapter 3. The MRO Review Process ............................................................................ 3 A. Administrative Review of the CCF ........................................................................... 3 I. State Initiatives and Laws ....................................................................................... 15 Chapter 4. Specific Drug Class Issues .......................................................................... 15 A. Amphetamines ....................................................................................................... 15 B. Cocaine ................................................................................................................
    [Show full text]
  • Lidocaine Infusion for Analgesia MOA Pharmacology 1
    Lidocaine Infusion for Analgesia MOA Pharmacology 1. Attenuation of proinflammatory effects: Ø Hepatic metabolism with high extraction ratio; Ø Blocks polymorphonuclear granulocyte priming, plasma clearance is 10 ml/kg/min13 reducing release of cytokines & reactive oxygen species1 Ø Adjust dose based on hepatic function and 2. Diminish nociceptive signaling to central nervous system: blood flow Ø Inhibition of G-protein-mediated effects2 Ø Renal clearance of metabolites Ø Reduces sensitivity & activity of spinal cord neurons Ø Context-sensitive half-time after a 3-day infusion is (glycine and NMDA receptor mediated)3,4 ∼20–40 min Ø Clinical effect of lidocaine tends to exceed the 5 3. Reduces ectopic activity of injured afferent nerves duration of the infusion by 5.5 times the half-life, supporting the putative preventive analgesia effect14 Perioperative Use Dosing Ø IV local anesthetic infusions have been used safely for pain control in the perioperative setting since the early 1950’s6,7 Infusion: 2mg/kg/hr (range 1.5-3 mg/kg/hr) Ø Reduce pain, nausea, ileus duration, opioid requirement, Loading dose: 1.5mg/kg (range 1-2 mg/kg) and length of hospital stay Ø Strongly consider bolus to rapidly achieve therapeutic concentration, otherwise steady state 9-12 Evidence for Specific Surgeries: reached in 4-8 hr Ø Strong: Open & laparoscopic abdominal; Reduces Max dose: 4.5 mg/kg postoperative pain, speeds return of bowel function, Ø Consider total dose from other local anesthetics reduces PONV, reduces length of hospital stay (e.g. regional anesthesia, periarticular injections, & Ø Moderate: Open prostatectomy, thoracic procedures, local infiltration) ambulatory surgery, and major spine; Reduces Continuous infusions up to 3 mg/kg/hr have been postoperative pain and opioid consumption shown to be safe Ø Moderate: Breast; Prevention of chronic postsurgical pain Ø Reduce infusion rate in patients with impaired Ø No benefit: Total abdominal hysterectomy, total hip drug metabolism & clearance (i.e.
    [Show full text]
  • Local Anesthetic Toxicity: Prevention and Treatment
    Local Anesthetic Toxicity: Prevention and Treatment John W. Wolfe, M.D. Staff Anesthesiologist Indiana University School of Medicine Indianapolis, Indiana John F. Butterworth, M.D. Chairman, Department of Anesthesia Indiana University School of Medicine Indianapolis, Indiana LESSON OBJECTIVES dine, and the site of injection on peak Upon completion of this lesson, the reader local anesthetic concentrations in blood. should be able to: 6. Describe the mechanism of local anes- 1. List the signs and symptoms of local thetic central nervous system toxicity. anesthetic toxicity. 7. Identify the risk factors for local anes- 2. Discuss the concept of "maximum safe thetic toxicity. doses of a local anesthetic." 8. Plan the treatment of local anesthetic- 3. Describe methods for reducing the risk of induced cardiac arrhythmias and cardiac local anesthetic toxicity. arrest. 4. Explain the treatment of local anes- 9. Describe the mechanism of local anes- thetic-related neurologic symptoms and thetic cardiovascular toxicity. toxic side effects. 10. Explain the dosage and proposed mech- 5. Discuss the effects of epinephrine, cloni- anism of lipid emulsion therapy. Current Reviews for Nurse Anesthetists designates this lesson for 1 CE contact hour in Clinical pharmacology/therapeutics. Introduction Mechanism of Cardiac and central nervous system (CNS) toxic Local Anesthetic Toxicity side effects of local anesthetics are relatively rare but potentially catastrophic complications of local and Local anesthetics normally produce their desired regional anesthesia. Fortunately, the likelihood of a effects on peripheral nerves by binding and inhibit- local anesthetic toxic event can be reduced by ad- ing voltage-gated sodium channels in neural cell herence to good technique.
    [Show full text]
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
    [Show full text]
  • A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS
    Application Note: 449 A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS Marta Kozak, Taha Rezai, Thermo Fisher Scientific, San Jose, CA Introduction Key Words Toxicology laboratories commonly use automated Scan Event 1 Scan Event 7 + Full Scan MS – Full Scan MS • ToxSpec immunoassays, gas chromatography-mass spectrometry Analyzer (GC-MS) and high pressure liquid chromatography-diode array detector (HPLC-DAD) techniques to perform • ToxID Software toxicology screening analyses. None of these techniques • LXQ Linear Ion are able to identify all the drugs and toxic compounds Trap that are potentially present in a sample. Implementation of liquid chromatography-mass spectrometry (LC-MS) for • Clinical toxicology screening provides specific and sensitive Toxicology analysis of drugs and toxic substances. The benefits of the • General LC-MS/MS screening methodology include a simple Unknown sample preparation procedure, ease of adding new Screening compounds to the screening method and fewer limitations based on compound volatility and thermal stability. In Scan Event 2-6 Scan Event 8-9 addition, Thermo Scientific ToxID automated toxicology + MS/MS on parent list – MS/MS on parent list screening software is able to automatically generate both Summary and Long Reports, avoiding the need for Figure 1: MS scan events manual analysis of each sample chromatogram. This application note describes the use of the Thermo Scientific LXQ ion trap mass spectrometer equipped with an ESI source and HPLC for identification of unknown compounds in human urine and human plasma. Step 1: Extract analytes from urine or plasma with SPE procedure Goal To develop a complete LC-MS/MS screening methodology which includes a sample preparation method, LC-MS Step 2: Analyze the samples method, spectra library, and data processing and reporting with LC-MS/MS method software.
    [Show full text]